- Home
- HSDT vs MTNB Comparison
HSDT vs MTNB Comparison
Compare HSDT & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- MTNB
- Stock Information
- Founded
- HSDT 2014
- MTNB 2013
- Country
- HSDT United States
- MTNB United States
- Employees
- HSDT N/A
- MTNB N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- HSDT Health Care
- MTNB Health Care
- Exchange
- HSDT Nasdaq
- MTNB Nasdaq
- Market Cap
- HSDT 2.5M
- MTNB 2.7M
- IPO Year
- HSDT N/A
- MTNB N/A
- Fundamental
- Price
- HSDT $0.49
- MTNB $0.56
- Analyst Decision
- HSDT Buy
- MTNB Hold
- Analyst Count
- HSDT 2
- MTNB 1
- Target Price
- HSDT $24.00
- MTNB N/A
- AVG Volume (30 Days)
- HSDT 236.6K
- MTNB 81.2K
- Earning Date
- HSDT 11-12-2024
- MTNB 11-13-2024
- Dividend Yield
- HSDT N/A
- MTNB N/A
- EPS Growth
- HSDT N/A
- MTNB N/A
- EPS
- HSDT N/A
- MTNB N/A
- Revenue
- HSDT $502,000.00
- MTNB N/A
- Revenue This Year
- HSDT N/A
- MTNB N/A
- Revenue Next Year
- HSDT $8.97
- MTNB N/A
- P/E Ratio
- HSDT N/A
- MTNB N/A
- Revenue Growth
- HSDT N/A
- MTNB N/A
- 52 Week Low
- HSDT $0.37
- MTNB $0.50
- 52 Week High
- HSDT $9.50
- MTNB $21.50
- Technical
- Relative Strength Index (RSI)
- HSDT 44.03
- MTNB 32.26
- Support Level
- HSDT $0.43
- MTNB $0.51
- Resistance Level
- HSDT $0.76
- MTNB $0.60
- Average True Range (ATR)
- HSDT 0.08
- MTNB 0.05
- MACD
- HSDT -0.01
- MTNB 0.07
- Stochastic Oscillator
- HSDT 17.91
- MTNB 38.65
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.